{"id":37684,"date":"2016-12-22T10:26:16","date_gmt":"2016-12-22T15:26:16","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=37684"},"modified":"2016-12-22T10:26:16","modified_gmt":"2016-12-22T15:26:16","slug":"corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684","title":{"rendered":"Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Initiates 1-Year Open-Label Extension For Phase II Study of Resunab"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)<\/strong> is initiating a 1-year, open-label extension trial of the underway Phase II clinical trial of Resunab for the cure of skin-predominant dermatomyositis. This extension was filed to and assessed by the U.S. Food and Drug Administration.<\/p>\n<p style=\"text-align: justify;\">The goal of this trial is to provide all registered subjects with the alternative of obtaining JBT-101 for 1-year after they close the 4-month, double-blind placebo controlled part of the trial and to collect long-term efficacy and safety on JBT-101. The efficacy and safety endpoints utilized in the double-blinded, placebo-controlled part of the study will be evaluated throughout the 1-year extension study.<\/p>\n<p style=\"text-align: justify;\"><strong>The expert view<\/strong><\/p>\n<p style=\"text-align: justify;\">Victoria P. Werth, M.D., the Principal Investigator of Phase II clinical trial of Resunab, stated that there is a clear unmet objective for effective therapeutic alternatives for individuals facing skin-predominant dermatomyositis. Since the release of the study, subjects have been very open to participating, and they expect a further understanding of the long-term efficacy and safety of JBT-101 using this study.<\/p>\n<p style=\"text-align: justify;\">Barbara White, M.D, the Chief Medical Officer of Corbus, said that they are delighted to provide the subjects who complete the blinded period of the skin-predominant dermatomyositis trial the opportunity to get JBT-101 for 1-year. The efficacy and safety data generated in this comprehensive period will be noteworthy to the clinical progression of JBT-101.<\/p>\n<p style=\"text-align: justify;\">Yuval Cohen, Ph.D., the CEO, said that they are extremely thrilled to execute this open-label extension in the next indication for JBT-101. It follows FDA nod of an open-label extension trial for systemic sclerosis in last April and the promising top-line Phase II clinical report in systemic sclerosis that they recently reported. They consider there is considerable overlap between these grave autoimmune diseases, and they anticipate reporting top-line report from the Phase II dermatomyositis trial in 3Q2017. It is an important achievement for the firm.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) is initiating a 1-year, open-label extension trial of the underway Phase II clinical trial of Resunab for the cure of [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":37686,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[12174,12172,12173],"stock_ticker":[],"class_list":["post-37684","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-corbus-pharmaceuticals-holdings-inc","tag-corbus-pharmaceuticals-holdings-inc-nasdaqcrbp","tag-nasdaqcrbp","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Initiates 1-Year Open-Label Extension For Phase II Study of Resunab - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Initiates 1-Year Open-Label Extension For Phase II Study of Resunab - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) is initiating a 1-year, open-label extension trial of the underway Phase II clinical trial of Resunab for the cure of [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-12-22T15:26:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/12\/Corbus-Pharmaceuticals.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Initiates 1-Year Open-Label Extension For Phase II Study of Resunab\",\"datePublished\":\"2016-12-22T15:26:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684\"},\"wordCount\":327,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/12\/Corbus-Pharmaceuticals.jpg\",\"keywords\":[\"Corbus Pharmaceuticals Holdings Inc\",\"Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)\",\"NASDAQ:CRBP\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684\",\"name\":\"Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Initiates 1-Year Open-Label Extension For Phase II Study of Resunab - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/12\/Corbus-Pharmaceuticals.jpg\",\"datePublished\":\"2016-12-22T15:26:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/12\/Corbus-Pharmaceuticals.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/12\/Corbus-Pharmaceuticals.jpg\",\"width\":600,\"height\":400},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Initiates 1-Year Open-Label Extension For Phase II Study of Resunab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Initiates 1-Year Open-Label Extension For Phase II Study of Resunab - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684","og_locale":"en_US","og_type":"article","og_title":"Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Initiates 1-Year Open-Label Extension For Phase II Study of Resunab - Wall Street PR","og_description":"Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) is initiating a 1-year, open-label extension trial of the underway Phase II clinical trial of Resunab for the cure of [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2016-12-22T15:26:16+00:00","og_image":[{"width":600,"height":400,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/12\/Corbus-Pharmaceuticals.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Initiates 1-Year Open-Label Extension For Phase II Study of Resunab","datePublished":"2016-12-22T15:26:16+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684"},"wordCount":327,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/12\/Corbus-Pharmaceuticals.jpg","keywords":["Corbus Pharmaceuticals Holdings Inc","Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)","NASDAQ:CRBP"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684","url":"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684","name":"Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Initiates 1-Year Open-Label Extension For Phase II Study of Resunab - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/12\/Corbus-Pharmaceuticals.jpg","datePublished":"2016-12-22T15:26:16+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/12\/Corbus-Pharmaceuticals.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/12\/Corbus-Pharmaceuticals.jpg","width":600,"height":400},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-initiates-1-year-open-label-extension-for-phase-ii-study-of-resunab-37684#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Initiates 1-Year Open-Label Extension For Phase II Study of Resunab"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/37684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=37684"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/37684\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/37686"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=37684"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=37684"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=37684"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=37684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}